Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation
Director departure
Appointed director

AVENUE THERAPEUTICS, INC. (ATXI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
09/29/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
09/28/2023 8-K Quarterly results
09/27/2023 8-K Other Events  Interactive Data
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights"
07/21/2023 8-K Quarterly results
07/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AVENUE THERAPEUTICS, INC. 2015 INCENTIVE PLAN STOCK OPTION AGREEMENT"
07/05/2023 4 Charles Faith L. (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 100,000 options to buy @ $1.14, valued at $114k
07/05/2023 4 Jin David (Interim PFO and COO) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 250,000 options to buy @ $1.14, valued at $285k
07/05/2023 4 ROSENWALD LINDSAY A MD (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 100,000 options to buy @ $1.14, valued at $114k
07/05/2023 4 KRANZLER JAY D (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 100,000 options to buy @ $1.14, valued at $114k
07/05/2023 4 Oltmans Curtis Gale (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 100,000 options to buy @ $1.14, valued at $114k
07/05/2023 4 Herskowitz Neil (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 100,000 options to buy @ $1.14, valued at $114k
07/03/2023 4 MacLean Alexandra (CEO) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 800,000 options to buy @ $1.14, valued at $912k
06/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/16/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Miami, FL – May 12, 2023 – Avenue Therapeutics, Inc. , a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2023. “Avenue is progressing its neuro-focused clinical stage pipeline and 2023 is off to a strong start with AJ201, a first in class small molecule for the treatment of Spinal and Bulbar Muscular Atrophy , now in an ongoing Phase 1b/2a clinical trial, and BAER-101, a potentially more tolerable drug for the treatment of epilepsy and acute anxiety, advancing toward Phase 1b studies in each indication. We..."
05/04/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/04/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/17/2023 8-K Quarterly results
04/04/2023 4 Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on AVENUE THERAPEUTICS, INC.
Txns: Granted 52,419 shares @ $0
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Appointed a new director
Docs: "Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates"
03/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
02/14/2023 SC 13G/A CVI Investments, Inc. reports a
02/14/2023 D Form D - Notice of Exempt Offering of Securities:
02/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/10/2023 8-K Quarterly results
02/03/2023 8-K Quarterly results
02/01/2023 8-K Quarterly results
01/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy